Research Analysts Offer Predictions for BCRX FY2025 Earnings

Key Points

• Cantor Fitzgerald has reduced their FY2025 earnings per share estimate for BioCryst Pharmaceuticals from $0.06 to $0.05 while maintaining an "Overweight" rating and a price target of $26.00.
• Several analysts have differing views on the stock, with price targets ranging from $8.00 to $30.00, and a consensus rating of "Moderate Buy" based on current market sentiment.
• Insider trading activity includes Director Theresa Heggie selling 70,000 shares at an average price of $8.51, resulting in a significant reduction of her ownership stake in the company.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will post earnings of $0.05 per share for the year, down from their previous forecast of $0.06. Cantor Fitzgerald has a "Overweight" rating and a $26.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

A number of other research firms also recently commented on BCRX. TD Cowen began coverage on BioCryst Pharmaceuticals in a research note on Wednesday. They issued a "buy" rating and a $30.00 price objective on the stock. Evercore ISI reissued an "in-line" rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Weiss Ratings restated a "sell (d-)" rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, JMP Securities lifted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $19.18.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $6.81 on Thursday. BioCryst Pharmaceuticals has a one year low of $6.00 and a one year high of $11.31. The stock's fifty day moving average is $7.90 and its 200-day moving average is $8.65. The company has a market capitalization of $1.43 billion, a PE ratio of -37.83, a P/E/G ratio of 1.28 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The firm's revenue was up 49.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.06) EPS.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its position in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. SG Americas Securities LLC boosted its position in BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after purchasing an additional 2,146 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in BioCryst Pharmaceuticals by 113.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company's stock valued at $283,000 after purchasing an additional 20,043 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in BioCryst Pharmaceuticals during the first quarter valued at $79,000. Finally, Cerity Partners LLC boosted its position in BioCryst Pharmaceuticals by 203.6% during the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company's stock valued at $273,000 after purchasing an additional 24,418 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.